New Studies Showcasing the Benefits of Accuray CyberKnife® Platform in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
Accuray Incorporated announced that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States.